Amgen and Micromet have announced early termination of the Hart-Scott-Rodino waiting period by the FTC. Amgen seeks to acquire Micromet with a tender offer for common stock at $11 per share in cash. Amgen is a biotechnology firm involved in human therapeutics; Micromet is a biopharmaceutical company for antibody-based therapies in cancer treatment.
Source: MarketWatch
Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)
Featured News
Cleveland-Cliffs Clears Regulatory Hurdle in Stelco Acquisition
Oct 9, 2024 by
CPI
Antitrust Showdown: Google Confronts Threats to Its Business in App Distribution, Search, and Advertising
Oct 9, 2024 by
CPI
X Returns to Brazil After Supreme Court Ruling Clears Path
Oct 9, 2024 by
CPI
Lawmakers Urge Another FTC Investigation Into PBMs Over Co-Manufacturing Deals
Oct 9, 2024 by
CPI
CVS and UnitedHealth Demand FTC Chair Recuse Herself from Insulin Price Suit
Oct 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh